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Background: In uveal melanoma (UM) with metastatic disease limited to the liver, the effect of an intrahepatic treatment
on survival is unknown. We investigated prospectively the efﬁcacy and toxicity of hepatic intra-arterial (HIA) versus system-
ic (IV) fotemustine in patients with liver metastases from UM.
Patients and methods: Patients were randomly assigned to receive either IV or HIA fotemustine at 100 mg/m2 on days
1, 8, 15 (and 22 in HIA arm only) as induction, and after a 5-week rest period every 3 weeks as maintenance. Primary end
point was overall survival (OS). Response rate (RR), progression-free survival (PFS) and safety were secondary end points.
Results: Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis. A total of
155 patients died and 16 were still alive [median follow-up 1.6 years (range 0.25–6 years)]. HIA did not improve OS (median
14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% conﬁdence interval (CI)
0.79–1.50, log-rank P = 0.59. However, there was a signiﬁcant beneﬁt on PFS for HIA compared with IV with a median of
4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002). The 1-year PFS rate was 24% in the
HIA arm versus 8% in the IV arm. An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%). In the IV
arm, the most frequent grade ≥3 toxicity was thrombocytopenia (42.1%) and neutropenia (62.6%), compared with 21.2%
and 28.7% in the HIA arm. The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity
(4.5%) apart from two toxic deaths.
Conclusion: HIA treatment with fotemustine did not translate into an improved OS compared with IV treatment, despite
better RR and PFS. Intrahepatic treatment should still be considered as experimental.
EudraCT number and ClinicalTrials.gov identiﬁer: 2004-002245-12 and NCT00110123.
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introduction
Uveal melanoma (UM) is a rare disease arising from the pig-
mented uveal tract of the eye. The incidence in Europe is 4.4
cases per million, varying between 2 in the south to 8 in the
north of Europe [1]. Around 5% of patients with UM have
distant metastases at diagnosis. Metastases appear usually
within a median of 3 years after the treatment of the primary
tumor with a range between 1 and 10 years. There is an unex-
plained hepato-tropism with the liver being the ﬁrst site of me-
tastases in up to 90% of patients and is the only site in 46% of
them [2]. Some clinical and histological features may predict the
development of metastases, tumor size being the most signiﬁ-
cant [3]. But chromosomal alterations like loss of chromosome
3 [4] or gene expression proﬁling have allowed to separate UM
with a good or poor prognosis [5]. It has been postulated recent-
ly that, inactivating somatic mutation of BRCA-1 associate
protein 1 (BAP1) on chromosome 3 might be one of the main
genetic events for the acquisition of metastatic potential [6].
At present, there are no standard therapies for metastatic
disease, and the treatments used for cutaneous melanoma have
resulted in minimal efﬁcacy [7]. The liver being the main site of
metastasis and carrying a worse prognosis, efforts were made to
develop locoregional intrahepatic strategies.
The rationale for HIA treatment is based on the fact that me-
tastases are fed primarily by the hepatic artery whereas the
normal liver tissue is supplied by the portal vein. HIA chemo-
therapy using fotemustine has been shown to produce a high
RR and encouraging median OS between 14 and 22 months
were reported [8, 9]. The prospective randomized phase III trial
(EORTC 18021) thus aimed to compare the efﬁcacy and safety
of HIA versus IV fotemustine in UM patients with metastases in
liver only.
patients andmethods
patients
Eligible patients were ≥18 years old, untreated, with histologically proven liver
metastases from UM. Patients with extrahepatic metastases, severe cardiac
disease or active duodenal ulceration were excluded. World Health
Organization (WHO) performance status (PS) 0–2, absolute neutrophile
count (ANC) ≥2.0 × 109/l, platelets count ≥100 × 109/l, hemoglobin ≥10 g/dl
and ASAT/ALAT, alkaline phosphatase, γ-glutamyltransferase, LDH <5 × the
upper normal limit (UNL), total bilirubin and serum creatinine <1.5 × UNL
were required. Women of child bearing potential and men should be using an
effective method of contraception.
The protocol was approved by the EORTC protocol review committee
and local ethical committees of the participating institutions. A written
informed consent was obtained from all patients before randomization in ac-
cordance with the declaration of Helsinki.
study design and treatment
The study is an open label randomized trial. Patients were centrally rando-
mized to receive either IV or HIA fotemustine in a 1:1 ratio, using the mini-
mization technique with stratiﬁcation for PS (0 versus 1 versus 2), LDH
(normal versus abnormal) and institution [10, 11]. The treatment schedule
and dose modiﬁcations are reported in supplementary data, available at
Annals of Oncology online.
treatment evaluation
The primary objective was to compare the overall survival (OS) deﬁned as the
time from date of randomization to the date of death from any cause. The
secondary end points were progression-free survival (PFS), response rate (RR),
pattern of progression, treatment-related toxicities and catheter-related compli-
cations. PFS was measured from the date of randomization to the date of pro-
gression or death. RR was based on measurable lesions according to RECIST
criteria version 1.0. Tumor measurements were assessed radiologically by CT
scan or MRI before start of treatment, then at week 7 from randomization
before the maintenance treatment phase, then every 9 weeks, similarly in both
arms, without central review. Stable disease was thus conﬁrmed every 9 weeks.
All responses had to be conﬁrmed not <4 weeks after the ﬁrst evaluation.
Treatment-related toxicities were evaluated according to CTC version 2.0.
statistical analysis
The study aimed to detect a 50% increase in the median OS between the IV
(8 months) and the HIA arms (12 months), corresponding to a hazard ratio
(HR) of 0.67 (two-sided α = 0.05 and β = 0.15). A total of 262 patients were
foreseen to be randomized over 3 years, of whom 220 had to be followed till
death.
Due to a slow accrual, an unplanned interim futility analysis was recom-
mended by the EORTC independent data monitoring committee (IDMC).
At the time of the interim analysis, 134 deaths were recorded. Using a
O’Brien-Fleming boundary, the observed treatment HR had to be >0.88 in
order to reject the hypothesis of superiority in OS of HIA over IV, with a
power of 80% [12]. This was the case, so the IDMC recommended closing
the trial to patient’s entry early for futility.
The Kaplan–Meier technique was used to estimate survival-type distribu-
tions, and standard errors (SE) of the estimates were obtained via
Greenwood formula [13]. The log-rank two-sided test was used for the com-
parison of the treatment outcome. The 95% conﬁdence interval (CI) of
medians was obtained via the Brookmeyer and Crowley’s nonparametric
method. The Cox proportional hazards model was used to adjust the treat-
ment comparison by factors used at randomization (LDH and performance
status). This model provided an estimated treatment HR, its conﬁdence
interval with a boundary proper to each analysis (ﬁrst and ﬁnal), and
a P-value (Wald test).
Main efﬁcacy analyses were carried out in the intention-to-treat (ITT)
population: all patients were considered in their initial randomized arm.
Sensitivity analyses for OS and PFS were carried out in all patients who actu-
ally started the treatment allocated by randomization. A second sensitivity
analysis was carried out for PFS analysis by censoring the follow-up at the
time of cross-over to the other arm. SAS 9.2 software (SAS Institute, Inc.,
Cary, NC) was used for statistical analyses.
results
From February 2005 to February 2011, 171 patients were rando-
mized. The primary OS analysis was based on a clinical cutoff
date of 20 March 2012 by which time 155 patients had died and
16 were still alive. The median follow-up from randomization
for the entire study was 5, 6 years (range 0.25–6 years) similar in
the two treatment groups. For the 16 patients alive, it was 1.6
years (range 0.25–6 years). Overall, 30 patients were still alive 2
years after randomization. The efﬁcacy population consisted in
86 in the HIA arm and 85 in the IV arm. Patient characteristics
were well balanced between treatment arms (supplementary
Table S1, available at Annals of Oncology online). However, in a
small subgroup of patients with LDH >ULN, an unbalance
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favoring the IV arm was observed, with 2 (2.4%) >2 × UNL
compared with 11 (12%) in the HIA arm.
Three patients were considered ineligible in the HIA arm: two
with metastases outside the liver, one with LDH >5 × the UNL
(supplementary Figure S1, available at Annals of Oncology
online). Among the patients treated, the reason for stopping treat-
ment was tumor progression or death in 37 patients (56.1%) in
the HIA arm and 59 patients (71.1%) in the IV arm. The median
(range) number of fotemustine cycles administered was 4 (1–17)
and 3 (1–19) in the HIA and IV arms, respectively. Treatment
discontinuation due to toxicity occurred in 14 (21.2%) (hemato-
logical n = 7, hepatic n = 3, septic shock n = 2, gastric ulcer n = 1,
arterial thrombosis n = 1) and 22 (26.5%) patients (hematological
n = 21, fatigue n = 1), respectively. In addition, in the HIA arm,
11 patients (16.7%) went off treatment due to catheter dysfunc-
tion. Since 20 patients in the HIA arm and 2 patients in the IV
arm and did not start the protocol treatment, safety analysis was
done on 66 and 83 patients, respectively.
efﬁcacy
Based on the intention-to-treat analysis (ITT), the OS was
similar in the HIAwhen compared with the IV group (HR, 1.09;
95% CI 0.79–1.50) (Figure 1). The median OS was 14.6 months
(95% CI 10.2–15.4) and 13.8 months (95% CI 10.2–17.2) in the
HIA and IV arms, respectively. At 2 years, 19.2% (SE 4.4%) sur-
vived in the HIA arm and 20.2% (SE 4.6%) in the IV arm. The
treatment comparison did not change when adjusted by stratiﬁ-
cation factors or if only the patients who received the treatment
according to protocol were considered.
The initial stratiﬁcation factors had an impact on OS. Patients
with a PS 0 had a longer median OS than patients with a PS 1
(14.7 versus 9.5 months) (supplementary Figure S2, available at
Annals of Oncology online). The median OS was 16.3 months
when LDH≤UNL, 10.3 months when LDH between UNL and
≤2 × UNL, and 4.6 months when LDH >2 × UNL (supplemen-
tary Figure S3, available at Annals of Oncology online).
In the ITT analysis, there were 9 (10.5%) responses (1 com-
plete, 8 partial) observed among the 86 patients in the HIA arm
and 2 partial responses (2.4%) among 85 patients in the IV arm
(P = 0.057). And considering the patients who started the proto-
col treatment (9/66 = 13.6% versus 2/83 = 2.4%), the difference
was signiﬁcant (P = 0.02). The median time to progression of
the responding patients was 9.0 and 8.3 months in HIA and IV
arms, respectively. Disease stabilization was reported 33 (38.4%)
versus 44 (51.8%) in the HIA and IV arm, respectively.
For the whole cohort of 171 patients, the median PFS was 4
months. On an ITT basis, there was a statistically signiﬁcant
(P = 0.002) increase in PFS in favor of HIA (HR, 0.62; 95% CI
0.45–0.84) (Figure 2). The median PFS was 4.5 months (95% CI
4.1–6.0) and 3.7 months (95% CI 2.0–4.1) for HIA and IV arms,
respectively, and the 1-year PFS rate was 19% versus 8%.
Adjusting by initial stratiﬁcation factors (PS and LDH), treatment
comparison provided similar results. Considering only the
patients who started the treatment allocated by randomization,
the HR was 0.53 (95% CI 0.38–0.75), and 0.49 when adjusted for
PS and LDH (three-categorical variable). The 1-year PFS rate was
24% in the HIA arm versus 8% in the IV arm.
The initial PS (1 versus 0) had no impact on PFS (HR 0.84).
Nevertheless, PFS was inﬂuenced by pretreatment LDH levels
considered as either two or as three variables: the 6-month PFS
rate was 40.4% (SE 4.9%), 28.8% (SE 5.9%) and 7.7% (SE 7.4%)
when LDH was ≤UNL or UNL≤ 2 × UNL or >2 × UNL,
respectively (Wald test P = 0.04).
First progression in the liver was observed in 54.8% in the
HIA arm compared with 89, 4% of the IV arm, whereas extrahe-
patic progression occurred in 26.2% in HIA arm and 5.0% in
the IV arm. When off study treatment, 25 patients in the HIA
arm received IV fotemustine, 3 had other intrahepatic therapies
and all the remaining had systemic dacarbazine-based treat-
ments. In the IV arm, one patient received HIA fotemustine and
four had other intrahepatic treatments. Five additional patients
with later progressions received intrahepatic treatment.
toxicity
The toxicity is summarized in Table 1. Hematological toxicity
was more frequent in the IV than in the HIA arm. Thus,
thrombocytopenia grade ≥3 was observed in 42.1% and in
21.2% in the IV and HIA arm, respectively. Neutropenia grade
≥3 was 62.6% in the IV arm and 28.7% in the HIA arm. But the
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Figure 1. Overall survival by treatment group: ITT analysis in all rando-
mized patients. O means observed events.
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Figure 2. PFS by treatment group: ITT analysis in all patients randomized.
O means observed events.
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incidence of infection or febrile neutropenia was not signiﬁ-
cantly different between the two arms. The nonhematological
toxicity was mainly related to HIA therapy, with abdominal
pain grade ≥3 in 12.1% of patients, and gastric ulcer in 3% of
them. Moreover, 31.8% had catheter-induced complications
(stenosis, thrombosis, dissection or misperfusion) and 4.5% had
liver toxicity grade ≥3 (partial necrosis, impaired liver function
tests). Two toxic deaths occurred in the HIA arm, one due to a
septic shock and the other to a mesenteric artery thrombosis fol-
lowed by a sepsis, and none in the IV arm.
discussion
UM is an orphan disease for which large prospective studies do
not exist and for which no efﬁcient treatment is known in
advanced stage. We present here the largest prospective rando-
mized trial ever conducted that aimed to determine the actual
outcome of patients with metastatic disease to the liver treated
by an investigational approach through a locoregional treatment
in the liver and compared with a similar cohort receiving intra-
venous chemotherapy.
Over the years, chemotherapy of metastatic UM has been
tested mainly in multiple phase II trials of small and highly
selected populations. It was based on regimens extrapolated
from cutaneous melanoma. But these are two distinct diseases
with a different pattern of metastases and different genetic
proﬁles [2]. Activating V600E mutation of B-RAF has not been
observed in UM [14]. On the contrary, 86% of UM exhibits
GNAQ/11 mutations [15, 16].
Single-agent treatment with dacarbazine or temozolomide
has been recognized as standard chemotherapy for metastatic
cutaneous melanoma. Their activity in UM has been limited to
a small phase II trials, where no responses were reported and
the median survival was 6.7 months [17]. Fotemustine is a
third-generation nitrosurea that was shown to be as active as
dacarbazine in cutaneous melanoma [18]. In UM, its IV admin-
istration however has been tested in association with interferon
α and IL-2 in 25 patients with an 8% RR and a 12.3-month
median OS [19]. Interestingly, the same group treated another
cohort of 23 patients with HIA Fotemustine and obtained a 22%
RR and similar median survival [19]. Fotemustine has been
accepted in some countries in Europe as a treatment option.
Due to its high liver extraction rate at ﬁrst pass, fotemustine has
been also tested as a HIA administration. The results of a few
phase II studies conﬁrmed a RR ranging from 22% to 40%, and
a median OS of 12–24 months [8, 9]. Multiple prognostic
factors might have inﬂuenced these results when compared with
the IV administration, and the strongest factor in multivariate
analysis has been the LDH level [8].
We thus conducted a randomized trial balanced for the most
important prognostic factors in order to compare the clinical
outcome of patients with only liver metastases treated with the
same chemotherapy administered either HIA or IV.
Our study conﬁrmed that IV fotemustine led to a low RR
(2.4%) and a high rate of progression (41.2%). These results are in
line with any IV chemotherapy regimens [7]. The HIA fotemus-
tine obtained a higher RR at 13.6% when considering patients
that received the treatment as per protocol. It was however lower
than the ones reported in the previous phase II trials.
In our study, PFS was inﬂuenced by the treatment type with a
median PFS of 4.5 and 3.7 months for the HIA and IV, respec-
tively. When considering only patients that received the treat-
ment according to protocol, the 1-year PFS was 24% in HIA and
8% in IV arm. The most recent small phase II studies of IV ther-
apies had median PFS ranging from 1.9 to 3 months [20].
The main end point of our study was however OS. The
improved RR and PFS did not translate into a signiﬁcant differ-
ence in median OS that was ∼14 months in both arms.
Crossover or second-line treatments are unlikely to have had a
major impact on OS. Similarly, a small randomized trial testing
in 92 patients another locoregional strategy, the percutaneous
hepatic perfusion with melphalan against systemic treatment,
did not show any improvement in OS [21]. The known prognos-
tic factors like PS or LDH level have had a major inﬂuence on
OS in our study too, and were quite well balanced between both
arms. The treatment comparisons did not change even when
adjusted for an increase prevalence of LDH≥ 2 × ULN in the
HIA arm. Some biological characteristics, i.e. the presence of a
Table 1. Adverse events
IV arm (N = 83) HIA arm (N = 66)
Grade Grade
1 2 3 4 Grade 3–4% 1 2 3 4 Grade 3–4%
Hematological
Hemoglobin 10 55 18 87.9 0 7 41 18 41.3
Leucocytes 21 29 25 2 32.5 18 15 10 2 18.1
Neutrophils 12 7 23 29 62.6 11 8 11 8 28.8
Thrombocytes 7 15 20 15 42.1 6 8 10 4 21.2
Nonhematological
Nausea-vomiting 27 10 0 0 0 24 12 3 0 4.5
Abdominal pain 27 6 1 0 1.2 9 14 7 1 12.1
Gastric ulcer 0 0 0 0 0 0 1 2 0 3.0
Catheter complications NA 9 3 7 1 12.0
Infection 0 7 3 0 3.6 0 8 1 2 4.5
Febril neutropenia 0 0 3 0 3.6 0 0 1 0 1.5
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GNA11 mutation [16], or the intratumoral immune status [22],
might have inﬂuenced these results.
The treatment could be given on an outpatient basis in both
arms reﬂecting the lack of major toxicity. In the IV arm, the tox-
icity was hematological without any increased risk of bleeding
or infection compared with the HIA arm. In the latter, the mor-
bidity was related mainly to catheter or hepatic arterial compli-
cations and liver toxicity that was the cause of treatment
discontinuation in 11 patients (17%). This catheter complication
rate correlated with the ﬁnding of similar multi-institutional
studies in uveal or colorectal cancer [23]. In conclusion, despite
an improved antitumor efﬁcacy as noticed by an enhanced RR
and an improved PFS, the HIA fotemustine did not increase the
OS of UM patients with liver metastases only. We propose to
consider intrahepatic treatment as an experimental approach
that may not be appropriate as a single modality. But its com-
bination with systemic targeted therapies, like MEK inhibitors
that have recently demonstrated promising efﬁcacy in UM [24],
might be considered in future studies, similarly to what has been
shown in other diseases [25–27].
acknowledgements
We warmly thank the EORTC Headquarters (data managers: S.
Vanderschaeghe, I. Jagiello, L. Polders, C. Kluyskens; project
manager: G. de Schaetzen; clinical research physicians: J. Flament,
S. Margerit, K. Stoitchkov; pharmacovigilance managers: M.-P.
Gauthier), and Mrs M. Gonin for typing the manuscript.
funding
This work was supported by European Organisation for
Research and Treatment of Cancer, and by Servier through an
Educational Grant (IRIS trial number CL3-10036), and by a do-
nation from the Schweitzerische Krebsliga from Switzerland
through the EORTC Charitable Trust.
disclosure
AT disclosed potential conﬂict of interest being consultant for
BMS, GSK, Amgen, and having received honoraria from these
companies. SN disclosed potential conﬂict of interest being con-
sultant for Pﬁzer, and Roche, GSK, Amgen, and having received
research funding from these companies. TJ disclosed potential
conﬂict of interest being consultant for BMS, and Roche and
having received honoraria from these companies. All remaining
authors have declared no conﬂict of interest.
references
1. Virgili G, Gatta G, Ciccolallo L et al. Incidence of uveal melanoma in Europe.
Ophthalmology 2007; 114(12): 2309–2315.
2. Diener-West M, Reynolds SM, Agugliaro DJ et al. Development of metastatic
disease after enrollment in the COMS trials for treatment of choroidal melanoma:
Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol
2005; 123(12): 1639–1643.
3. Shields CL, Furuta M, Thangappan A et al. Metastasis of uveal melanoma
millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009;
127(8): 989–998.
4. Prescher G, Bornfeld N, Hirche H et al. Prognostic implications of monosomy 3 in
uveal melanoma. Lancet 1996; 347(9010): 1222–1225.
5. Onken MD, Ehlers JP, Worley LA et al. Functional gene expression analysis
uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006;
66(9): 4602–4609.
6. Harbour JW, Onken MD, Roberson ED et al. Frequent mutation of BAP1 in
metastasizing uveal melanomas. Science 2010; 330(6009): 1410–1413.
7. Bedikian AY, Legha SS, Mavligit G et al. Treatment of uveal melanoma metastatic
to the liver: a review of the M. D. Anderson Cancer Center experience and
prognostic factors. Cancer 1995; 76(9): 1665–1670.
8. Leyvraz S, Spataro V, Bauer J et al. Treatment of ocular melanoma metastatic to
the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15(7): 2589–2595.
9. Siegel R, Hauschild A, Kettelhack C et al. Hepatic arterial Fotemustine
chemotherapy in patients with liver metastases from cutaneous melanoma is as
effective as in ocular melanoma. Eur J Surg Oncol 2007; 33(5): 627–632.
10. Freedman LS, White SJ. On the use of Pocock and Simon’s method for balancing
treatment numbers over prognostic factors in the controlled clinical trial.
Biometrics 1976; 32(3): 691–694.
11. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic
factors in the controlled clinical trial. Biometrics 1975; 31(1): 103–115.
12. Fleming TR, Harrington DP, O’Brien PC. Designs for group sequential tests. Control
Clin Trials 1984; 5(4): 348–361.
13. Kalbﬂeisch JD, Prentice RL. The Survival Analysis of Failure Time Data.
2nd edition. Hokboken, NJ: John Wiley & Sons, Inc. 2002.
14. Greaves WO, Verma S, Patel KP et al. Frequency and spectrum of BRAF mutations
in a retrospective, single-institution study of 1112 cases of melanoma. J Mol
Diagn 2013; 15: 220–226.
15. Van Raamsdonk CD, Bezrookove V, Green G et al. Frequent somatic mutations
of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457(7229):
599–602.
16. Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations in GNA11 in uveal
melanoma. N Engl J Med 2010; 363: 2191–2199.
17. Bedikian AY, Papadopoulos N, Plager C et al. Phase II evaluation of temozolomide
in metastatic choroidal melanoma. Melanoma Res 2003; 13(3): 303–306.
18. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in
patients with disseminated malignant melanoma: a phase III study. J Clin Oncol
2004; 22(6): 1118–1125.
19. Becker JC, Terheyden P, Kampgen E et al. Treatment of disseminated ocular
melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J
Cancer 2002; 87(8): 840–845.
20. Schmittel A, Schmidt-Hieber M, Martus P et al. A randomized phase II trial of
gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic
uveal melanoma. Ann Oncol 2006; 17(12): 1826–1829.
21. Pingpank JF, Hughes MS, Faries MB et al. A phase III random assignment trial
comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard
of care for patients with hepatic metastases from metastatic ocular or cutaneous
melanoma. J Clin Oncol 2010; 28(suppl; abstr LBA8512): 18s.
22. Toivonen P, Mäkitie T, Kujala E et al. Microcirculation and tumor-inﬁltrating
macrophages in choroidal and ciliary body melanoma and corresponding
metastases. Invest Ophthalmol Vis Sci 2004; 45(1): 1–6.
23. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy
after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;
341(27): 2039–2048.
24. Carvajal RD, Sosman JA, Quevedo F et al. Phase II study of selumetinib versus
temozolomide in gnaq/Gna11 mutant uveal melanoma. J Clin Oncol 2013; 31.
25. Kemeny NE, Melendez FDH, Capanu M et al. Conversion to resectability using
hepatic artery infusion plus systemic chemotherapy for the treatment of
unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27
(21): 3465–3471.
26. Sansonno D, Lauletta G, Russi S et al. Transarterial chemoembolization plus sorafenib:
a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular
carcinoma: a randomized clinical trial. Oncologist 2012; 17(3): 359–366.
27. Leyvraz S, Keilholz U. Ocular melanoma: what’s new? Curr Opin Oncol 2012;
24(2): 162–169.
 | Leyvraz et al. Volume 25 | No. 3 | March 2014
original articles Annals of Oncology
